Elamipretide

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Elamipretide
Elamipretide structure.svg
Clinical data
Synonyms H-D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH2; D-Arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
Identifiers
CAS Number
PubChem CID
UNII
Chemical and physical data
Formula C32H49N9O5
Molar mass 639.80 g·mol−1

Elamipretide (also known as SS-31 and Bendavia)[1][2] is a small mitochondrially-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that appears to reduce the production of toxic reactive oxygen species and stabilize cardiolipin.[3]

Stealth Peptides, a privately held company, was founded in 2006 to develop intellectual property licensed from several universities including elamipretide; it subsequently changed its name to Stealth BioTherapeutics.[4][5]

As of November 2017 Stealth had obtained an orphan designation in the US for use in mitochondrial myopathy and had started a Phase III trial in that indication.[2]

References[edit]

  1. ^ "Recommended INN List 75" (PDF). WHO Drug Information. 30 (1): 111. 2016. 
  2. ^ a b "Elamipretide". AdisInsight. Retrieved 29 November 2017. 
  3. ^ Kloner, RA; Shi, J; Dai, W (February 2015). "New therapies for reducing post-myocardial left ventricular remodeling". Annals of translational medicine. 3 (2): 20. doi:10.3978/j.issn.2305-5839.2015.01.13. PMC 4322169Freely accessible. PMID 25738140. 
  4. ^ Valigra, Lori (April 9, 2012). "Stealth Peptides sees positive results from Bendavia". Boston Business Journal. 
  5. ^ Dolgin, Elie (11 February 2016). "New drugs offer hope for mitochondrial disease". STAT.